These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

12580 related items for PubMed ID: 10360420

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cysteine and indole derivatives as markers for malignant melanoma.
    Hartleb J, Arndt R.
    J Chromatogr B Biomed Sci Appl; 2001 Nov 25; 764(1-2):409-43. PubMed ID: 11817040
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
    Meyer T, Hauschild A, Kromminga A, Hartleb J, Arndt R, Christophers E, Stockfleth E.
    Melanoma Res; 2002 Oct 25; 12(5):471-7. PubMed ID: 12394189
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 5-S-cysteinyldopa in urine and tumors.
    Hara H, Chino K, Kawanami T, Sameshima T, Morishima T.
    J Dermatol; 1992 Nov 25; 19(11):806-8. PubMed ID: 1293167
    [Abstract] [Full Text] [Related]

  • 8. Pre-study and in-study validation of a SPE-LC-MS-MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma.
    Martin G, Mansion F, Houbart V, Paquet P, Rorive A, Chiap P, Crommen J, Servais AC, Fillet M.
    Talanta; 2011 Apr 15; 84(2):280-6. PubMed ID: 21376945
    [Abstract] [Full Text] [Related]

  • 9. Significance of 5-S-Cysteinyldopa as a Marker for Melanoma.
    Wakamatsu K, Fukushima S, Minagawa A, Omodaka T, Hida T, Hatta N, Takata M, Uhara H, Okuyama R, Ihn H.
    Int J Mol Sci; 2020 Jan 09; 21(2):. PubMed ID: 31936623
    [Abstract] [Full Text] [Related]

  • 10. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T, Tatsumi F, Fukada E, Saito M, Fujita M, Nagashima N, Hanawa S.
    Arch Dermatol Res; 1983 Jan 09; 275(2):76-9. PubMed ID: 6409012
    [Abstract] [Full Text] [Related]

  • 11. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K, Yokochi M, Naito A, Kageshita T, Ito S.
    Melanoma Res; 2003 Aug 09; 13(4):357-63. PubMed ID: 12883361
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
    Sasaki Y, Shimizu H, Naka W, Takeshita E, Nishikawa T.
    Acta Derm Venereol; 1997 Sep 09; 77(5):379-81. PubMed ID: 9298132
    [Abstract] [Full Text] [Related]

  • 16. Improved solid-phase extraction and liquid chromatography with electrochemical detection of urinary catecholamines and 5-S-L-cysteinyl-L-dopa.
    Huang TH, Wall J, Kabra P.
    J Chromatogr; 1988 Oct 28; 452():409-18. PubMed ID: 3149647
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
    Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, Ono T, Saida T, Takata M, Tsuchida T, Uhara H, Yamamoto A, Yamazaki N, Naito A, Ito S.
    Melanoma Res; 2002 Jun 28; 12(3):245-53. PubMed ID: 12140381
    [Abstract] [Full Text] [Related]

  • 20. HPLC analysis of pheomelanin degradation products in human urine.
    Takasaki A, Nezirević D, Arstrand K, Wakamatsu K, Ito S, Kågedal B.
    Pigment Cell Res; 2003 Oct 28; 16(5):480-6. PubMed ID: 12950724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 629.